Boston Scientific will buy the UK medical technology group through a newly created company called Bravo Bidco.
Bravo Bidca has offered 840p a share in cash for BTG, a premium of 36.6% to its Monday closing price. The offer is a 51% premium to the acquisition target’s volume-weighted average ...Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: subs@globalcapital.com
Corporate access
To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.